Role of Lipid Rafts in Gamma Secretase Processing of APP
About the Research Project
Program
Award Type
Other
Award Amount
$300,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
A2006104
Summary
Alzheimer’s disease (AD) is the major cause of dementia in the elderly. Mutations in genes encoding Presenilins and Amyloid Precursor Protein (APP) cause early onset AD. These mutant proteins increase the production of toxic beta-amyloid peptides (Aβ), which accumulate in the brains of individuals with AD. Production and accumulation of Aβ are central events in AD pathogenesis. This proposal seeks to investigate the regulation of Aβ production. Aβ is released from truncated APP by the action of “y-secretase”, composed of Presenilins and three other proteins. Specialized microdomains of cellular membranes, called lipid rafts, seem to play important role in Aβ production. Dr. Thinakaran seeks to investigate how y-secretase complex is selectively targeted to lipid rafts. He also proposes to examine the regulation of y-secretase complex and APP by a variety of molecular and cell biological approaches. A better understanding of the relationship between y-secretase and lipid rafts will shed more light on the mechanisms involved in Aβ production. Information stemming from the biochemical, molecular and cellular investigations will likely be critical in developing novel and rational strategies for therapeutic intervention for AD aimed at reducing Aβ burden.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD